A global virtual event dedicated to the latest heart failure treatment strategies to support better patient outcomes

Overview

Translational Medicine Academy (TMA) in partnership with Radcliffe Cardiology are delighted to announce the return of e-SPACE Heart Failure to be held 18-19 October 2024.

Last year’s event brought together over 50 leading experts from across the globe, drawing a live international audience of thousands. Click here to watch e-SPACE Heart Failure 2023 on-demand.

e-SPACE Heart Failure 2024 will once again provide top-tier free virtual education and will both optimise geographical reach whilst delivering both global and regional insight. The thoughtfully curated programme will explore how leading experts are incorporating heart failure guidelines into clinical practice and will offer the latest information on patient profiling in heart failure for tailored medical therapy.

Building on the tremendous success of previous years, this event will once again bring together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.

Underpinned by this combined expertise in educational content and delivery, and led by an international faculty of global standing, e-SPACE Heart Failure 2024 is designed to support you in achieving optimal clinical outcomes in heart failure management.

The e-SPACE HF 2024 conference has been accredited by EBAC®. Information about CME certificates will be sent by email after the conference.

Programme

(Please note this programme is subject to change)

Day 1

9:00 AM - 10:00 AM (BST)
Plenary Session
Session 1 – Practical implementation of GDMT in the clinical setting

Chairs – Vijay Chopra and Tarek Bekfani

  • Physicians perceptions towards implementing GDMT in HF – Gianluigi Savarese

  • Contemporary GDMT sequencing and titration – Jasper Brugts

  • Dietary sodium and fluid intake in HF – Justin Ezekowitz

  • Panel discussion

 



10:10 AM - 10:50 AM (BST)
Meet the Expert
SGLT2 inhibitors in real life: everything the clinician needs to know

Andrew Coats and Patricia Campbell



Supported by an unrestricted educational grant from Boehringer Ingelheim


11:00 AM - 12:00 PM (BST)
Plenary Session
Session 2 – SGLT2s in clinical practice

Chairs – John Atherton and Tarek Bekfani

  • SGLT2 in post MI HF – Javed Butler

  • SGLT2 inhibitors early initiation – Clara Inés Saldarriaga

  • SGLT2 and cardiorenal protection – Faiez Zannad

  • Panel discussion

 



12:10 PM - 1:10 PM (BST)

Special session 1 – Cardiac rhythm management devices: cornerstones of comprehensive, patient-centred HF care The-DIRECT-HF initiative

ChairsJaved Butler and Shelley Zieroth

  • Welcome from Medtronic – Hela Ben Hamouda

  • Introduction to the DIRECT HF educational programme – Javed Butler

  • Cardiac rhythm management devices: cornerstones of comprehensive, patient-centred HF care – Shelley Zieroth and Wilfried Mullens

  • Prevention of sudden cardiac death: relevance in contemporary HF care – Christophe Leclercq, Gianluigi Savarese and Biykem Bozkurt

  • ICD therapy in HF: the patient’s perspective

  • Panel discussion – Biykem Bozkurt, Javed Butler, Loreena Hill, Giuseppe Rosano, Gianluigi Savarese and Shelley Zieroth

  • Conclusion – Shelley Zieroth

 



The DIRECT HF educational programme is supported by Medtronic


1:20 PM - 1:50 PM (BST)
Meet the Expert
GDMT implementation in HF: how to tackle clinical inertia?

  • Current state of GDMT implementation in HF: clinical and organisational barriers

  • Tackling clinical inertia to improve GDMT use and improve patient outcomes

Giuseppe Rosano and Stephen Greene

 



Supported by unrestricted educational grant funding from AstraZeneca


2:00 PM - 3:00 PM (BST)
Plenary Session
Session 3 – Obesity and weight management in HF

ChairsStefan Anker and Petar Seferovic

  • Obesity and HF: epidemiology and mechanisms – Naveed Sattar

  • Weight management in HFpEF – Shelley Zieroth

  • Overview of current therapeutic agents – Shahzeb Khan

  • The role of GLP-1RA and HF – Peter Rossing

  • Panel discussion

 



3:10 PM - 3:50 PM (BST)

Special session 2 – Face to face with cardiac amyloidosis

Thibaud Damy and Lawrence Sherman



4:00 PM - 5:00 PM (BST)
Plenary Session
Session 4 – Managing cardiomyopathy in HF

ChairsArnt Kristen and Carsten Tschöpe

  • Epidemiology and clinical features – Arnt Kristen

  • Differential diagnosis – Michelle Kittleson

  • Management of cardiac amyloidosis – Marianna Fontana

  • New approaches in the management of HCM – Arnt Kristen

  • Panel discussion



5:10 PM - 5:40 PM (BST)
Meet the Expert
Management of transthyretin amyloid cardiomyopathy (ATTRCM): optimising patient pathways

Marianna Fontana and Arnt Kristen



Supported by unrestricted educational grant funding from AstraZeneca


7:00 PM - 8:00 PM (BST)
Plenary Session
Session 5 – Cardiac rhythm in HF

ChairsAndrea Russo and Fausto Pinto

  • The role of CRM devices in HF – Klaus Witte

  • Prevention of sudden arrhythmic death in HFrEF – Carsten Israel

  • CRT in HFrEF for whom and when – William Abraham

  • A modular communicative leadless pacing-defibrillator system – Reinoud Knops

  • Panel discussion

 



8:10 PM - 8:50 PM (BST)
Meet the Expert
SGLT2 inhibitors in real life: everything the clinician needs to know

Andrew Coats and Patricia Campbell



Supported by an unrestricted educational grant from Boehringer Ingelheim


9:00 PM - 10:00 PM (BST)
Plenary Session
Session 6 – Devices in HF; time to reassess their place?

Chairs – Ileana Piña and Stefan Anker

  • Neuromodulation therapy for HFrEF – David Duncker

  • CCM: benefits of early implementation – Marat Fudim

  • The role of MCS in acute HF – Dirk Westermann

  • Sleep apnea – William Abraham

  • Panel discussion

 




Day 2

8:20 AM - 8:50 AM (BST)
Meet the Expert
IV iron in clinical practice: experts’ perspectives

Patricia Campbell and Paul Kalra



Supported by an unrestricted educational grant from Pharmacosmos


9:00 AM - 10:00 AM (BST)
Plenary Session
Session 7 – Enabling GDMT in HF

Chairs – David Sim and Alicia Chan

  • The role of potassium binders – Gianluigi Savarese

  • Non-steroidal MRAs – Gerasimos Filippatos

  • The role of SGLT2i in preventing hyperkalemia – Joao Ferreira

  • Panel discussion

 



10:10 AM - 10:50 AM (BST)
Meet the Expert
Hyperkalemia in HF: clinical impact and long-term management

ChairShelley Zieroth

  • Hyperkalemia in HF: impact on GDMT use and outcomes – Gianluigi Savarese

  • Long-term potassium management in HF: practical guidance – Shahzeb Khan



Supported by unrestricted educational grant funding from AstraZeneca


11:00 AM - 12:00 PM (BST)
Plenary Session
Session 8 – Iron deficiency: the totality of evidence

Chairs – Mitja Lainscak and Giuseppe Rosano

  • Iron deficiency in HFrEF – Ewa Jankowska

  • Latest data on ferric derisomaltose – Paul Kalra

  • How to keep to the diagnosis simple? – John Cleland

  • Panel discussion

 



1:00 PM - 1:50 PM (BST)
Symposium
SGLT2 inhibitors in heart failure: updates on prevention and treatment

Stefan Anker, Biykem Bozkurt, Michael Böhm and Clara Ines Saldarriaga



Supported by an unrestricted educational grant from Boehringer Ingelheim


2:00 PM - 3:00 PM (BST)
Plenary Session
Session 9 – Managing HFpEF in 2024

Chairs – Harriette Van Spall and Biykem Bozkurt

  • The role of non-steroidal MRAs – Muthiah Vaduganathan

  • The effect of iron on patients with HFpEF – Stefan Anker

  • The potential role of interleukin-6 (IL-6) antibodies in HFpEF – Mark Petrie

  • Panel discussion

 



3:10 PM - 3:50 PM (BST)
Meet the Expert
Non-steroidal MRAs: evolving role in heart failure

Gerasimos Filippatos and Muthiah Vaduganathan



Supported by an unrestricted educational grant from Bayer


4:00 PM - 5:00 PM (BST)
Plenary Session
Session 10 – Valvular heart disease

Chairs – Piotr Ponikowski and Ahmed Bennis

  • Drugs and interventions in HF – Marianna Adamo

  • Targeting FMR – Stefan Anker

  • Management of TR in HF – Karl Kresoja

  • Panel discussion

 



7:00 PM - 8:00 PM (BST)
Plenary Session
Session 11 – Remote monitoring and team approaches in the management of HF

ChairsMaria Rosa Costanzo and JoAnn Lindenfeld

  • Latest experience with haemodynamic monitoring – JoAnn Lindenfeld

  • Reducing HF hospitalisation by disease management programme – Nicolas Girerd

  • Reveal Linq – Javed Butler

  • Panel discussion

 



8:00 PM - 9:00 PM (BST)
Meet the Expert
Replay: Management of transthyretin amyloid cardiomyopathy (ATTRCM): optimising patient pathways

Marianna Fontana and Arnt Kristen



Supported by unrestricted educational grant funding from AstraZeneca



Faculty

William Abraham
Prof William Abraham
The Ohio State University, Ohio, US
Marianna Adamo
Dr Marianna Adamo
Civil Hospital of Brescia, Brescia, IT
Stefan Anker
Prof Stefan Anker
Charité Campus Virchow-Klinikum, Berlin, DE
John Atherton
Prof John Atherton
Royal Brisbane and Women’s Hospital, Brisbane, AU
Tarek Bekfani
Dr Tarek Bekfani
University hospital Magdeburg A.o.R., Magdeburg, DE
Ahmed Bennis
Prof Ahmed Bennis
Ibn Rochd University Hospital, Casablanca, MA
Michael Böhm
Prof Michael Böhm
Saarland University Hospital, Homburg, DE
Biykem Bozkurt
Prof Biykem Bozkurt
Baylor College of Medicine, Texas, US
Jasper Brugts
Prof Jasper Brugts
Erasmus University Medical Centre, Rotterdam, NL
Javed Butler
Prof Javed Butler
Baylor Scott and White Research Institute, Texas, US
Patricia Campbell
Dr Patricia Campbell
Craigavon Area hospital, Portadown, UK
Alicia Chan
Dr Alicia Chan
Western HeartCare, Henley Beach, AU
Vijay Chopra
Prof Vijay Chopra
Max Super Speciality Hospital, New Delhi, IN
John Cleland
Prof John Cleland
University of Glasgow, Glasgow, UK
Andrew Coats
Prof Andrew Coats
Heart Research Institute, NSW, AU
Thibaud Damy
Prof Thibaud Damy
University Hospital Henri Mondor, Creteil, FR
David Duncker
Prof David Duncker
Hannover Heart Rhythm Center, Hannover, DE
Justin Ezekowitz
Prof Justin Ezekowitz
University of Alberta, Edmonton, CA
Joao Ferreira
Dr Joao Ferreira
University of Porto, Porto, PT
Gerasimos Filippatos
Prof Gerasimos Filippatos
National and Kapodistrian University of Athens, Athens, GR
Marianna Fontana
Prof Marianna Fontana
University College London, London, UK
Marat Fudim
Dr Marat Fudim
Duke University, Durham, US
Nicolas Girerd
Dr Nicolas Girerd
University Hospital of Nancy, Nancy, FR
Stephen Greene
Dr Stephen Greene
Duke Clinical Research Institute, North Carolina, US
Clara Inés Saldarriaga
Prof Clara Inés Saldarriaga
University of Antioquia, Medellín, CO
Carsten Israel
Dr Carsten Israel
Bethel-Clinic, Bielefeld, DE
Ewa Jankowska
Prof Ewa Jankowska
Wrocław Medical University, Wrocław, PL
Shahzeb Kahn
Shahzeb Kahn
Baylor Scott & White Health, Texas, US
Paul Kalra
Prof Paul Kalra
Portsmouth Hospitals NHS Trust, Portsmouth, UK
Michelle Kittleson
Dr Michelle Kittleson
Cedars-Sinai Heart Institute, California, US
Reinoud Knops
Dr Reinoud Knops
Amsterdam University Medical Center, NL
Karl Kresoja
Dr Karl Kresoja
Heart Center of Leipzig, Leipzig, DE
Arnt Kristen
Prof Arnt Kristen
University of Heidelberg, Heidelberg, DE
Mitja Lainscak
Dr Mitja Lainscak
General Hospital Murska Sobota, Murska Sobota, SI
JoAnn Lindenfeld
Dr JoAnn Lindenfeld
Vanderbilt University Medical Center,Tennessee, US
Milton Packer
Dr Milton Packer
Baylor University Medical Center, Texas, US
Mark Petrie
Prof Mark Petrie
University of Glasgow, Glasgow, UK
Ileana Piña
Dr Ileana Piña
Thomas Jefferson University, Philadelphia, US
Fausto Pinto
Prof Fausto Pinto
Santa Maria Hospital - CHULN, Lisbon, PT
Piotr Ponikowski
Prof Piotr Ponikowski
Wroclaw Medical University, Wroclaw, PL
Maria Rosa Costanzo
Dr Maria Rosa Costanzo
Midwest Cardiovascular Institute, Illinois, US
Giuseppe Rosano
Prof Giuseppe Rosano
St Georges Medical School, London, UK
Peter Rossing
Prof Peter Rossing
University of Copenhagen, Copenhagen, DK
Andrea Russo
Dr Andrea Russo
Cooper Medical School of Rowan University, New Jersey, US
Naveed Sattar
Prof Naveed Sattar
University of Glasgow, Glasgow, UK
Gianluigi Savarese
Prof Gianluigi Savarese
Karolinska Institute, Stockholm, SE
Petar Seferovic
Prof Petar Seferovic
University Clinical Center of Serbia, Belgrade, RS
Lawrence Sherman
Lawrence Sherman
Meducate Global
David Sim
Dr David Sim
National Heart Centre Singapore, SG
Carsten Tschöpe
Prof Carsten Tschöpe
German Heart Centre Berlin, Berlin, DE
Muthiah Vaduganathan
Prof Muthiah Vaduganathan
Brigham and Women's Hospital, Massachusetts, US
Harriette Van Spall
Prof Harriette Van Spall
McMaster University, Hamilton, CA
Dirk Westermann
Prof Dirk Westermann
University Heart Center Freiburg-Bad Krozingen, Freiburg, DE
Klaus Witte
Prof Klaus Witte
University of Leeds, Leeds, UK
Faiez Zannad
Prof Faiez Zannad
University of Lorraine, Vandoeuvre-Les-Nancy, FR
Shelley Zieroth
Prof Shelley Zieroth
St. Boniface Hospital, Winnipeg, CA

Learning Objectives

  • Review the burden of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) as one of the leading causes of disability and mortality worldwide
  • Understand the latest guideline recommendations and discuss their applicability according to patients phenotypes
  • Discuss the implementation in clinical practice of the four foundational therapies and additional drugs and devices to improve patient outcomes
  • Develop a comprehensive understanding of best practices for the screening, diagnosis and management of the patient with heart failure and comorbidities
  • Translate the findings of recent studies and guidelines into optimal patient management

Target Audience

  • Heart Failure Specialists
  • General Cardiologists
  • General Practitioners (GPs)
  • Nurses, Pharmacists, and other Allied Healthcare Professionals

Sponsors

If you’re interested in becoming an educational partner or sponsor at this event, please contact sales@radcliffe-group.com

About Translational Medicine Academy

Our ambition at the Translational Medicine Academy® (TMA) is to bring medical findings from bench to bedside and into the working lives of physicians and the care of patients. In seeking to improve therapeutic approaches, TMA works with its International Scientific Advisory Board on Critical Mission Areas® of public health importance in domains where there are educational shortcomings among physicians and unmet healthcare needs among patients.

Gathered around a Scientific Advisory Board of experts, the Translational Medicine Academy is an international non-profit Foundation with headquarter in Basel, and offices in Paris, and the US. TMA’s funding includes private donations from individuals and educational grants from governments, non-governmental organizations and corporations.

For more information on TMA, please visit www.tmacademy.org.

About Radcliffe Cardiology

We are Radcliffe, a knowledge network for the cardiovascular community

We’re here to bring cardiovascular knowledge, insight and innovation to life for clinicians around the world, using our communications and creative expertise, our platforms and connections across the community to help transform theory into practice faster and more effectively.

We bring medical knowledge to life

From great science writing and smart journal editing, the curation of evidence based and peer-reviewed content, to engaging new formats that cut through the noise, we believe that communication is at the heart of great healthcare.

Our work is underpinned by 3 core principles:

  • We build on the best science
  • We work hands-on with our community
  • We bring fresh thinking


Our promise is that we’ll equip you with the latest knowledge and skills you need, to do the best for your patients.

For more information on Radcliffe Cardiology, please visit www.radcliffecardiology.com